Approaches to target IgE antibodies in allergic diseases. 2018

Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France; Université Pierre et Marie Curie, Paris, France.

IgE is the antibody isotype found at the lowest concentration in the circulation. However IgE can undeniably play an important role in mediating allergic reactions; best exemplified by the clinical benefits of anti-IgE monoclonal antibody (omalizumab) therapy for some allergic diseases. This review will describe our current understanding of the interactions between IgE and its main receptors FcεRI and CD23 (FcεRII). We will review the known and potential functions of IgE in health and disease: in particular, its detrimental roles in allergic diseases and chronic spontaneous urticaria, and its protective functions in host defense against parasites and venoms. Finally, we will present an overview of the drugs that are in clinical development or have therapeutic potential for IgE-mediated allergic diseases.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069444 Omalizumab An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA. Xolair
D000076722 Drug Development The entire process of bringing a new drug to the market. It includes both preclinical and clinical testing, and regulatory approval. Computational Prediction of Drug-Target Interactions,Drug Target Prediction,Medication Development,Pharmaceutical Development,Development, Drug,Development, Medication,Development, Pharmaceutical,Drug Target Predictions,Prediction, Drug Target,Target Prediction, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018926 Anti-Allergic Agents Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) Anti-Allergic,Anti-Allergic Agent,Anti-Allergy Drug,Antiallergic,Antiallergic Agent,Antiallergic Drug,Anti-Allergics,Anti-Allergy Drugs,Antiallergic Agents,Antiallergic Drugs,Antiallergics,Antiallergy Agents,Agent, Anti-Allergic,Agent, Antiallergic,Agents, Anti-Allergic,Agents, Antiallergic,Agents, Antiallergy,Anti Allergic,Anti Allergic Agent,Anti Allergic Agents,Anti Allergics,Anti Allergy Drug,Anti Allergy Drugs,Drug, Anti-Allergy,Drug, Antiallergic,Drugs, Anti-Allergy,Drugs, Antiallergic

Related Publications

Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
February 1994, The Journal of investigative dermatology,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
January 2018, Clinical and translational allergy,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
January 2007, Advances in immunology,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
December 1979, La Pediatria,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
January 1976, International archives of allergy and applied immunology,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
September 1969, Proceedings of the Royal Society of Medicine,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
January 1978, Medicinski arhiv,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
May 2005, Nihon rinsho. Japanese journal of clinical medicine,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
January 1999, Pediatric pulmonology. Supplement,
Bianca Balbino, and Eva Conde, and Thomas Marichal, and Philipp Starkl, and Laurent L Reber
January 1999, International archives of allergy and immunology,
Copied contents to your clipboard!